Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma

The purpose of this study is to validate of a predictive nomogram of response or resistance to targeted therapies in metastatic clear cell renal cell carcinoma

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metastatic Clear Cell Renal Cell Carcinoma Clear-cell metastatic renal cell carcinoma

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Rennes

Rennes, 35033, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients with metastatic ccRCC
Underwent nephrectomy at the University Hospital of Rennes
treated by sunitinib first line treatment

Exclusion criteria

translocation renal cell carcinoma
other targeted therapies before the sunitinib

Treatment and study plan

Sunitinib

Drug

Primary outcomes

Primary refractory patients (Progression Free Survival (PFS)

Time frame: at 3 months

Sponsors and collaborators

Lead sponsor

Rennes University Hospital

Other

Registry information

Acronym: RTKI

Important dates

Study start: 2014
Primary completion: 2015
Study completion: 2017
First posted: Jul 28, 2016
Registry last updated: Jun 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed